What is HC Wainwright's Forecast for ITOS FY2029 Earnings?

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for iTeos Therapeutics in a research note issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth expects that the company will earn $1.19 per share for the year. HC Wainwright has a "Buy" rating and a $46.00 price objective on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.13.

Several other brokerages also recently commented on ITOS. Wells Fargo & Company reduced their target price on iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, March 6th. Wedbush reissued an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Finally, JPMorgan Chase & Co. lowered their target price on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th.

Remove Ads

iTeos Therapeutics Stock Performance

iTeos Therapeutics stock traded up $0.11 during trading hours on Friday, hitting $7.06. 521,820 shares of the stock were exchanged, compared to its average volume of 450,690. The stock has a market capitalization of $269.65 million, a P/E ratio of -2.24 and a beta of 1.38. The business's 50-day moving average is $7.52 and its two-hundred day moving average is $9.29. iTeos Therapeutics has a 12 month low of $6.67 and a 12 month high of $18.75.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Point72 DIFC Ltd bought a new stake in shares of iTeos Therapeutics during the third quarter worth $31,000. Point72 Asia Singapore Pte. Ltd. bought a new position in iTeos Therapeutics in the fourth quarter valued at about $42,000. Virtus ETF Advisers LLC increased its position in iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after purchasing an additional 3,293 shares during the period. Forefront Analytics LLC bought a new stake in iTeos Therapeutics during the 4th quarter worth about $85,000. Finally, Graham Capital Management L.P. acquired a new position in iTeos Therapeutics during the 4th quarter valued at about $85,000. Institutional investors and hedge funds own 97.16% of the company's stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.